RaQualia Pharma (TSE:4579) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4579 RaQualia Pharma Inc TSE:4579
59 GF Score
Price 円454.00
GF Value 円310.56
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is RaQualia Pharma FFO per Share?

FFO per Share only applies to REITs.

TSE:4579
59GF Score
RaQualia Pharma Inc TSE:4579
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is RaQualia Pharma (TSE:4579) Overvalued in 2026?

Based on GuruFocus' analysis, RaQualia Pharma stock appears to be overvalued. The current stock price of 円454.00 is trading 46.2% above its estimated GF Value™ of 円310.56. GuruFocus considers RaQualia Pharma to be Significantly Overvalued.

Key valuation signals for TSE:4579:

  • FFO per Share:
  • GF Value™: 円310.56 vs. price of 円454.00 (46.2% above fair value)
  • GF Score™: 59/100 with 4 warning signs

No single metric tells the full story. See the TSE:4579 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

RaQualia Pharma Business Description

Address 1-21-19 Meieki Minami, Nakamura-ku, Nagoya, JPN, 470-2341
RaQualia Pharma Inc operates as a research and development-centered biotechnology company, generating revenue by creating the seeds for novel medicine and licensing them to pharmaceutical companies. The company manages the Sales and licensing of intellectual property for fundamental technologies related to pharmaceutical compounds and candidate compounds for clinical development. Its product portfolio includes, Tegoprazan (K-CAB), Galliprant and Elura both under Veterinary Medicines. The pipeline products include Potassium-Competitive Acid Blocker, Ghrelin Receptor Agonist, TRPM8 Blocker and 5-HT4 Agonist studied under different phases of development.
59GF Score

Get the complete analysis for TSE:4579

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円454.00
Price
円310.56
GF Value